latest abn-amro report: $1.09 target

http://money.ninemsn.com.au/article.aspx?id=719567

"ABN Amro rates as Buy - The broker notes that while US market penetration of the company's lead product Evamist is slower than anticipated, it is still trending upwards. Otherwise, the broker expects a licensing deal for Ellavie outside of the US by the end of FY09 and finalisation of recruitment of a Phase III trial for Tesosterone MD-Lotion. Lower earnings see FY09-10 EPS forecasts cut by 18.5% and 28.8%, which sees the target price drop to $1.09 (from A$2.05), but otherwise the Buy is maintained."